Advancing Management of Allergic Rhinitis in the Pediatric Care Setting: The Role of Oral Tablet Immunotherapy is organized by Integrity Continuing Education Inc.
Release date: June 27, 2024
Expiration date: December 27, 2024
Description:
Allergic rhinitis with or without conjunctivitis (AR/C) in children and adolescents is a commonly misunderstood, misdiagnosed, and mistreated condition. AR/C exerts a significant effect on quality of life and has deleterious effects on sleep, academic performance, family functioning, and involvement in outdoor activities. Fortunately, there have been advances in the diagnosis and treatment of AR/C that support improved diagnosis and care of patients with inadequate relief from symptom-relieving therapies, including broadly available specific immunoglobulin E (lgE) tests, advances in understanding of immune mechanisms, and newer allergen immunotherapies including oral tablet immunotherapy.
This program will review these important updates to provide clinicians with the knowledge and skills to provide care to children and adolescents with AR/C that is aligned with the latest evidence and best practices.
Learning Objectives:
Upon completion of this educational activity, participants should be able to:
Credit Designation
Integrity CE, LLC designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Pharmacist Accreditation Statement
Global Education Group is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education with Commendation.
Credit Designation
Global Education Group designates this continuing education activity for 0.75 contact hour(s) (0.075 CEUs) of the Accreditation Council for Pharmacy Education.
Copyrights © 2026 eMedEvents Corporation, All Rights Reserved